<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002435</url>
  </required_header>
  <id_info>
    <org_study_id>136A</org_study_id>
    <secondary_id>CS 112010-999</secondary_id>
    <nct_id>NCT00002435</nct_id>
  </id_info>
  <brief_title>A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients</brief_title>
  <official_title>Study of the Activity of Thymic Humoral Factor (THF Gamma 2) on HIV Load in HIV-Positive Individuals With CD4+ Cell Counts in the Range of 200-500 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load&#xD;
      based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its&#xD;
      persistence when administered in combination with an antiretroviral nucleoside derivative&#xD;
      (zidovudine; AZT). To assess the effects of THF gamma 2 on T-cells, quality of life, and&#xD;
      progression of disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients receive 12 weeks of AZT before being randomized to self-administer one of two&#xD;
      doses of THF gamma 2 or placebo for 15 consecutive days and then twice weekly for an&#xD;
      additional 50 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymic Humoral Factor</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  AZT or another antiretroviral agent (marketed or investigational under a Treatment&#xD;
             IND).&#xD;
&#xD;
          -  Primary prophylaxis for Pneumocystis carinii pneumonia (PCP), toxoplasmosis, and&#xD;
             Mycobacterium avium-intracellulare (MAI) if patient's CD4 count decreases to &lt; 200&#xD;
             cells/mm3.&#xD;
&#xD;
          -  Other marketed drugs as required.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity and be either asymptomatic or have persistent generalized&#xD;
             lymphadenopathy (PGL).&#xD;
&#xD;
          -  No history of symptoms in Category B or C of 1993 Case Definition, other than oral&#xD;
             candidiasis following previous broad-spectrum antibiotic therapy.&#xD;
&#xD;
          -  Mean CD4 of 200-500 cells/mm3.&#xD;
&#xD;
          -  HIV-1 positive PCR RNA.&#xD;
&#xD;
          -  Ability to self-administer study drug by IM injection.&#xD;
&#xD;
          -  Ability to tolerate AZT at 600 mg daily during first 8 weeks of run-in period (if AZT&#xD;
             naive) OR tolerated AZT at &gt;= 500 mg daily for at least 3 months but no more than 12&#xD;
             months prior to randomization.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Malignancy.&#xD;
&#xD;
          -  Hematuria.&#xD;
&#xD;
          -  Proteinuria &gt; 1+.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Non-antiretroviral agents with known or suspected activity against HIV.&#xD;
&#xD;
          -  Investigational new drugs that are not antiretroviral agents distributed under a&#xD;
             Treatment IND.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
        Myositis within the past 6 months.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Experimental therapy, including interleukin-2, interferon, erythropoietin, or&#xD;
             filgrastim nucleoside within 6 weeks prior to study entry.&#xD;
&#xD;
          -  Prior antiretroviral therapy (AZT-naive patients only).&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 6 weeks prior to study entry:&#xD;
&#xD;
          -  Blood transfusion or blood products. Active alcoholism, drug abuse, or a mental or&#xD;
             psychiatric problem sufficient to prevent adequate compliance with study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCI</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Community Based AIDS Treatment Group - COMBAT</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Veterans Administration Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottlieb Med Group</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mem Hosp Hollywood</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodgame Med Group</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea Village Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland Veterans Adm Med Ctr / Rsch &amp; Education Grp</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Alfred F Burnside Jr</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Physicians Inc</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 1998</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>thymic humoral factor gamma 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

